

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Emmanuel Hubert DEMONT et al.

JCO5 Rec'd PCT/PTO 13 SEP 2005

International Application No.: PCT/EP2004/002644

International Filing Date: March 11, 2004

For: Novel Compounds

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP2004/002644 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: EV332065765US

Date of Mailing: 9/13/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

JC05 Rec'd PCT/PTO 13 SEP 2005

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 13 September 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		To be assigned	
				FILING DATE		Herewith	
				APPLICANT		10/547349 DEMONTAGAL.	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60133USw	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1.	WO01/70672	9/27/2001	PCT			
	2.	WO02/002505	1/10/2002	PCT			
	3.	WO02/02506	1/10/2002	PCT			
	4.	WO02/02512	1/10/2002	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	5.	BERGE et al., Journal of Pharmaceutical Sciences 66(1):1-19 (1977).					
	6.	CAI et al., BACE1 is the major β -secretase for generation of A β peptides by neurons, Nature Neuroscience 4(3):233-234 (2001).					
	7.	CHAN et al., New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate, Tetrahedron Letters 39:2933-2936 (1998).					
	8.	CONNOR, Cathepsin D in Handbook of Proteolytic Enzymes, Barrett, A.J. (Eds) Academic Press London pp828-836(1998).					
	9.	DE STROOPER AND KONIG, A firm base for drug development, Nature 402:471-472 (1999).					
	10.	GREENE AD WUTS, The Role of Protective Groups in Organic Synthesis, J. Wiley and Sons 3 rd Ed. (1999).					
	11.	JENSEN et al., Stereoelctronic Substituent Effects in Polyhydroxylated Piperidines and Hexahydropyridazines, Chem. Eur. J., 8(5):1218-1226 (2002).					
	12.	KERINS AND O'SHEA, Generation of Substituted Styrenes via Suzuki Cross-Coupling of Aryl halides with 2,46-Trivinylcyclotriboroxane, J. Org. Chem. 67:4968-4971 (2002).					
	13.	LUO et al., Mice deficient in BACE1, the alzheimer's β -secretase, and abolished β -amyloid generation, Nature Neuroscience 4(3):231-232 (2001).					
	14.	NASLUND et al., Correlation Between Elevated Levels of Amyloid β -Peptide in the Brain and Cognitive Decline, JAMA 283(12):1571-1577 (2000).					
	15.	ROBERDS et al., BACE knockout mice are healthy despite lacking the primary β -secretase activity in brain: implications for alzheimer's disease therapeutics, Human Molecular Genetics 10(12):1317-1324 (2001).					
	16.	SELKOE, Alzheimer's Disease: Genes, Proteins, and Therapy, Physiological Reviews 81(2):741-766 (2001).					
	17.	SELWOOD et al., Synthesis and biological Evaluation of Novel Pyrazoles and Indazoles as Activators of the Nitric Oxide Receptor, Soluble Guanylate Cyclase, J. Med. Chem. 44:78-93 (2001).					
	18.	VASSAR AND CITRON, A β -Generating Enzymes: Recent Advances in β - and γ -Secretase Research, Neuron 27:419-422 (2000).					
	19.	YOUNKIN, Amyloid β vaccination: reduced laques and improved cognition, Nature Medicine 7(1):18-19 (2001).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							